Sinovac Biotech Ltd.

Symbol: SVA

NASDAQ

6.47

USD

Market price today

  • -1.8213

    P/E Ratio

  • -0.0016

    PEG Ratio

  • 464.06M

    MRK Cap

  • 0.00%

    DIV Yield

Sinovac Biotech Ltd. (SVA) Financial Statements

On the chart you can see the default numbers in dynamics for Sinovac Biotech Ltd. (SVA). Companys revenue shows the average of 905.627 M which is 7.215 % gowth. The average gross profit for the whole period is 822.362 M which is 34.779 %. The average gross profit ratio is 0.619 %. The net income growth for the company last year performance is 0.000 % which equals -0.553 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Sinovac Biotech Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.000. In the realm of current assets, SVA clocks in at 12126.396 in the reporting currency. A significant portion of these assets, precisely 11312.693, is held in cash and short-term investments. This segment shows a change of -0.157% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 661.44, if any, in the reporting currency. This indicates a difference of 0.855% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 64.029 in the reporting currency. This figure signifies a year_over_year change of 0.000%. Shareholder value, as depicted by the total shareholder equity, is valued at 8921.421 in the reporting currency. The year over year change in this aspect is -0.044%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 609.489, with an inventory valuation of 180.72, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 79.51.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014201320122011201020092008200720062005200420032001200019991998

balance-sheet.row.cash-and-short-term-investments

47642.9511312.713415.31176.3
203
177.1
114.4
62.4
63.8
91.3
107.2
91.2
104.3
103.1
82.3
32.9
17.1
9.2
7.4
2.6
1.4
0.1
0
0.1
0

balance-sheet.row.short-term-investments

23255.047034.61806.4135.2
50.3
18.9
0
0
0
0
0
0
0
1.5
7.3
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

3031.89609.5952.4253.5
113.7
77.5
66.2
49.8
39
40.7
31.9
23.4
17.8
25.8
25.5
19.5
17
9.7
5.5
3.4
1.5
0
0
0
0

balance-sheet.row.inventory

1005.83180.7375.5105.8
27.8
25.1
19.6
14.1
18.7
18.7
14.3
10.5
8.1
14.9
9.6
7.4
3.7
2.1
0.8
0.5
1
0
0
0
0

balance-sheet.row.other-current-assets

244.9523.5171.924.7
5
4.5
3.6
4.4
1.8
4.1
3.8
1.1
1.8
3.6
1.9
0.3
1.4
0.7
2.2
1.2
0
0.1
0.1
0
0

balance-sheet.row.total-current-assets

51925.6212126.414915.11560.3
349.6
284.2
203.9
130.7
128.5
154.8
157.3
126.3
132
147.3
119.3
62.3
39.2
21.7
16.3
8.5
4
0.2
0.2
0.2
0

balance-sheet.row.property-plant-equipment-net

4522.661173.31084304.4
83.3
71.4
77
67.8
64.2
67.6
68.7
69.7
76.5
64
22.3
19.3
15.9
13
12.5
10
7.5
0
0
0
0

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

241.2479.541.29.7
8
8.3
9
8.7
9.6
10.6
11.7
12.1
1.3
1.3
0.7
1.1
1.4
1.7
1.9
1.2
2.5
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

241.2479.541.29.7
8
8.3
9
8.7
9.6
10.6
11.7
12.1
1.3
1.3
0.7
1.1
1.4
1.7
1.9
1.2
2.5
0
0
0
0

balance-sheet.row.long-term-investments

2672.16661.4655.87.1
0
0
0
0
0
0
0.2
0.3
0.4
0.5
2.6
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

286.6671.15226.9
11.4
5.8
9.3
3.9
0.6
0.5
0.1
0.4
0.4
0.5
0.5
0.6
0.7
0.6
0.7
0.9
0
0
0
0
0

balance-sheet.row.other-non-current-assets

5.222.80-7.1
0
0.1
0
0.1
0
5
2.9
0.3
5.7
1.2
0
0
0.3
0
0
1.8
0.9
0.1
0.1
0
0

balance-sheet.row.total-non-current-assets

7727.921988.21833.1341
102.7
85.6
95.3
80.6
74.4
83.7
83.4
82.5
83.9
67.1
26.2
20.9
18.3
15.3
15
13.9
10.9
0.1
0.1
0.1
0

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

59653.5414114.616748.21901.3
452.3
369.8
299.2
211.4
202.9
238.5
240.7
208.8
215.9
214.4
145.5
83.2
57.4
37
31.3
22.4
14.9
0.2
0.3
0.2
0

balance-sheet.row.account-payables

1232.2419.858.630.5
5.8
5.5
6.8
1.8
1.7
3
6.1
2.2
2.9
2.3
3.8
1.4
0.8
0.7
0.7
0.3
1.5
0.1
0
0
0

balance-sheet.row.short-term-debt

244.9510.615.142.6
13.1
3.3
18.2
33.6
24.2
50
19.5
3.3
4.7
10.4
17.7
8
6.8
2.7
2.4
2.6
0.8
0
0
0
0

balance-sheet.row.tax-payables

1717.27256.61302.142.1
3
1.9
9.8
4.4
2.5
1.8
2.5
2.3
6
2.5
9.9
1.5
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

319.5464129.893.8
7.2
10.6
21.9
9.4
0.8
1.8
32.1
34.4
17.3
10.1
0.4
2.2
4.1
3.8
2.7
0.2
0.6
0
0.2
0.5
0

Deferred Revenue Non Current

23.164.54.94.2
4
6.1
4.5
3
4.7
14.7
15.8
14.8
13.8
5.9
10
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

1130.64---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

5839.641028.12246.7227.3
60.1
44.5
123
52.6
22.8
21.3
22.2
45.7
61.4
43.6
45.3
11.9
12.8
8.5
5.7
3.7
1.2
0.1
0.7
0.1
0

balance-sheet.row.total-non-current-liabilities

1474.78310.3459.3101.6
12.9
19.6
29.5
15.4
8.3
17
47.9
49.2
31.1
20.8
10
5
4.1
3.8
2.7
0.2
0.6
0
0.2
0.5
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

291.7658.5122.889
6.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

6733.751401.92872.2781.2
100.1
77.9
122.1
81.7
66.4
96.8
97.1
79.3
70.6
66.6
61
26.3
24.5
15.7
11.5
6.9
4
0.1
1
0.6
0

balance-sheet.row.preferred-stock

0.06000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

0.40.10.10.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

29231.1372267141.8144.2
56.7
23.8
9.1
-11.9
-10
-6.4
-4.7
-12.2
2.7
3.9
14
-1.7
-7.1
-12.9
-11.6
-6.2
-0.7
-1.1
-0.9
-0.4
0

balance-sheet.row.accumulated-other-comprehensive-income-loss

4980.031154.71644.970.3
29.2
24.5
26.6
15
21.6
24.6
25.9
23.6
21.8
18.4
14.1
4.1
5
1.8
2.3
0.4
1
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

2710.7540.6540.6531.8
208
205
115.3
112.7
109.9
108.2
107.4
106.2
105.4
104.2
42.5
47.2
32.1
30.3
27.2
18.2
5.8
1.1
0.2
0
0

balance-sheet.row.total-stockholders-equity

36381.738921.49327.4746.5
294
253.4
151.2
115.8
121.7
126.6
128.7
117.7
129.9
126.4
70.7
49.7
30
19.2
18
12.4
6.1
0.1
-0.7
-0.4
0

balance-sheet.row.total-liabilities-and-stockholders-equity

59653.5414114.616748.21901.3
452.3
369.8
299.2
211.4
202.9
238.5
240.7
208.8
215.9
214.4
145.5
83.2
57.4
37
31.3
22.4
14.9
0.2
0.3
0.2
0

balance-sheet.row.minority-interest

16538.053791.24548.6373.7
58.2
38.5
26
13.9
14.9
15.2
15
11.7
15.4
21.3
13.8
7.2
2.9
2.1
1.8
3.1
4.7
0
0
0
0

balance-sheet.row.total-equity

52919.7812712.7138761120.1
352.2
291.9
177.1
129.7
136.5
141.7
143.6
129.4
145.3
147.8
84.5
56.9
32.9
21.3
19.8
15.6
10.9
0.1
-0.7
-0.4
0

balance-sheet.row.total-liabilities-and-total-equity

59653.54---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

25927.1976962462.3135.2
50.3
18.9
0
0
0
0
0
0
0
1.5
10
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-debt

564.4874.7144.9136.4
20.3
13.9
40.1
43
25
51.8
51.7
37.7
22
20.5
17.7
10.2
10.9
6.5
5.1
2.8
1.4
0
0.2
0.5
0

balance-sheet.row.net-debt

-23823.43-4203.5-11463.9-904.6
-132.4
-144.3
-74.3
-19.4
-38.8
-39.5
-55.6
-53.5
-82.3
-81.1
-57.3
-22.7
-6.1
-2.8
-2.3
0.2
-0.1
-0.1
0.1
0.4
0

Cash Flow Statement

The financial landscape of Sinovac Biotech Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.000. The company recently extended its share capital by issuing 0, marking a difference of 0.000 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to -5760470000.000 in the reporting currency. This is a shift of 0.905 from the previous year. In the same period, the company recorded 156.6, -35.08, and -4.47, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -263.17 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 26.24, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009200820072006200520042003200120001999

cash-flows.row.net-income

303.4988.114458.9185.2
65.2
36.1
36.7
-3.1
-0.2
0.3
11.6
-18.7
-0.4
-12.6
30.4
12.2
7.7
-0.7
-5.1
-4.7
-0.9
-0.2
-0.5
-0.4

cash-flows.row.depreciation-and-amortization

242156.686.84
4.8
5.1
4.9
5.3
6.5
8.1
6.4
4.5
4.8
4.2
2.2
1.8
1.4
1.3
1.1
0.9
0.7
0.1
0
0

cash-flows.row.deferred-income-tax

-121.41-83265.1-11.2
-5.7
3.1
-4.9
-1
-0.3
-0.2
-2.2
0
2.8
-1.7
1.3
-0.5
-0.2
-0.4
0
-0.9
0
0
0
0

cash-flows.row.stock-based-compensation

-227.69149.57.710.2
3
4.3
1
2.4
1
0.3
0.3
0.3
0.2
0.5
0.4
0.1
2.7
1
-0.1
0.4
0
0
0
0

cash-flows.row.change-in-working-capital

-774.99-1081.2460.6282.8
-28.2
-44
20
-18.7
-2.3
-18.9
-10.4
-6.9
2.9
-14.3
14.7
-3.8
-8.2
-4.6
-0.2
-1.6
-1.3
0
0
0

cash-flows.row.account-receivables

305.3289.6-710.4-128
-40.2
-13.1
-13.5
-15.1
0
-9.7
-7.3
-4.3
5.5
1
-5
-1.4
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-42.6930.4-334.1-77.7
-3.7
-9.4
-5.5
-3
0
-6.1
-7.2
-0.4
-1.9
-8.6
-5.4
-4.3
-1.8
-2.5
-0.3
0.6
0.3
0
0
0

cash-flows.row.account-payables

-59.21-67.4720.9131.8
6.8
-6.2
33.4
2.7
-0.3
-3.5
4.5
-1
1.2
-0.7
5.6
2.3
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

-978.39-1333.8784.2356.8
8.8
-15.3
5.6
-3.3
-2
0.4
-0.4
-1.2
-1.9
-6
25.1
1.9
-6.4
-2.1
0.1
-2.3
-1.6
0
0
0

cash-flows.row.other-non-cash-items

363.31-0.873.48.3
0
3.2
2.1
1.2
-0.4
0.3
-0.1
4.5
3.6
9.6
-0.6
0.7
3.7
2.8
2.7
4.7
-0.2
0
0
0

cash-flows.row.net-cash-provided-by-operating-activities

-215.29000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-589.86-403.4-720-127.7
-10.6
-5.6
-11.9
-12.7
-5.3
-10.9
-5.1
-16.2
-15.5
-25.4
-4.3
-4
-2.5
-1.1
-2.4
-1.7
-0.7
0
0
0

cash-flows.row.acquisitions-net

0.658.9-13.7541.1
0
0
0
0.9
0.8
0
0
0
0
0.2
0
0
0
0
-2.3
-1.1
-0.4
0
0
0

cash-flows.row.purchases-of-investments

-18542.7-11658.5-8826.6-201.7
-50.7
-19.7
0
0
0
0
0
0
0
-1.5
-7.3
0
0
0
0
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

10373.996327.56567.5124.6
18.8
0
0
0
0
0
0
0
1.5
7.3
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-investing-activites

-0.16-35.1-30.8-541
0
0
0
0
0
-0.1
0
0
0.1
0.3
-0.1
0
0
0.6
-0.2
-0.3
0.4
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

-8757.92-5760.5-3023.6-204.8
-42.5
-25.3
-11.9
-11.8
-4.5
-11
-5.2
-16.2
-13.8
-19.2
-11.7
-4
-2.4
-0.6
-4.9
-3
-0.7
0
0
0

cash-flows.row.debt-repayment

-220.34-4.5-46.8-10.4
-3.3
-43.9
-38.7
-24.9
-46.8
-16.6
-4.1
-4.8
-10.7
-21.1
-10.2
-7.2
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

2.67012
0
85.3
1.3
0.3
0.7
0.5
0.8
0.5
0.7
62.3
0.7
9.8
1.6
0.9
5.5
5.3
1
0
0.2
0

cash-flows.row.common-stock-repurchased

0020.60
0
0
0
0
0
0
0
0
0
0
-0.3
-0.4
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0-263.2-1875.90
0
0
0
0
0
0
0
0
0
0
-3.8
-2.9
0
0
-0.4
0
0
0
0
0

cash-flows.row.other-financing-activites

316.226.24.3601
5
22.8
36.1
52.3
21.9
21.4
17.7
21.6
10.5
17.1
19
9
3.9
3.1
6
0.5
2.5
0.1
0.2
0

cash-flows.row.net-cash-used-provided-by-financing-activities

517.41-241.4-1896.7592.6
1.7
64.2
-1.3
27.8
-24.2
5.3
14.4
17.3
0.6
58.2
5.3
8.3
5.6
4
11.1
5.8
3.6
0.1
0.4
0.5

cash-flows.row.effect-of-forex-changes-on-cash

-620.71-560.8137.327.2
-0.6
-4.7
4
-2.3
-1.5
-1.4
1.2
2
1.9
2
0
1
0.4
0.1
0.1
0
0
0
0
0

cash-flows.row.net-change-in-cash

-9076.51-7333.410569.6894.3
-2.3
42.2
50.5
0
-26
-16.7
15.3
-13
2.7
26.6
42.1
15.8
7.8
1.9
4.7
1.2
1.1
0
-0.1
0.1

cash-flows.row.cash-at-end-of-period

13850.434286.411619.81050.2
155.9
158.2
116
65.4
63.8
89.8
106.5
91.2
104.3
101.6
75
32.9
17.1
9.2
7.4
2.6
1.4
0.1
0
0.1

cash-flows.row.cash-at-beginning-of-period

22926.9411619.81050.2155.9
158.2
116
65.4
65.5
89.8
106.5
91.2
104.3
101.6
75
32.9
17.1
9.2
7.4
2.6
1.4
0.3
0
0.1
0

cash-flows.row.operating-cash-flow

-215.29-770.715352.5479.3
39.1
7.9
59.8
-13.9
4.2
-10.1
5.6
-16.3
13.9
-14.3
48.4
10.5
4.3
-1.6
-1.6
-1.5
-1.7
-0.1
-0.5
-0.3

cash-flows.row.capital-expenditure

-589.86-403.4-720-127.7
-10.6
-5.6
-11.9
-12.7
-5.3
-10.9
-5.1
-16.2
-15.5
-25.4
-4.3
-4
-2.5
-1.1
-2.4
-1.7
-0.7
0
0
0

cash-flows.row.free-cash-flow

-805.15-1174.114632.6351.7
28.4
2.3
47.8
-26.6
-1.1
-21
0.4
-32.4
-1.5
-39.7
44.1
6.5
1.8
-2.8
-4
-3.2
-2.5
-0.1
-0.5
-0.4

Income Statement Row

Sinovac Biotech Ltd.'s revenue saw a change of -1.000% compared with the previous period. The gross profit of SVA is reported to be 0. The company's operating expenses are 0, showing a change of 0.000% from the last year. The expenses for depreciation and amortization are 156.6, which is a 0.000% change from the last accounting period. Operating expenses are reported to be 0, which shows a 0.000% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -1.000% year-over-year growth. The operating income is 0, which shows a 0.000% change when compared to the previous year. The change in the net income is 0.000%. The net income for the last year was 0.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032001200019991998

income-statement-row.row.total-revenue

1960.6201492.819374.9
510.6
246.1
229.7
174.3
72.4
67.4
62.9
71.8
49.2
56.8
33.4
84.2
46.5
33.5
15.4
8.6
6.5
2.8
0.5
0.3
0
0

income-statement-row.row.cost-of-revenue

916.390684.51072.2
67.2
32.5
24.7
20.2
22.4
18.4
15.5
20.5
19.1
21.1
16.7
20.1
9.9
6.5
4.2
2.3
1.9
1.1
0.3
0.2
0
0

income-statement-row.row.gross-profit

1044.230808.318302.7
443.4
213.6
204.9
154.1
50
49
47.5
51.3
30.1
35.7
16.7
64.1
36.6
27
11.1
6.3
4.5
1.8
0.2
0.1
0
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

595.9---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

1.370301.8-89.9
0.5
0.9
0.3
0
0.1
-0.2
1.2
0.3
-0.1
0.3
0.1
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.operating-expenses

1739.3801269.2748.4
227.6
144.7
159.5
108.6
49.1
45.3
45.5
41.2
49.1
31.9
28.8
23.3
20.9
13.6
10.7
11.1
9.5
2.3
0.4
0.5
0.4
0

income-statement-row.row.cost-and-expenses

2655.7701953.61820.7
294.8
177.2
184.3
128.9
71.4
63.7
61
61.7
68.2
53
45.5
43.3
30.8
20.1
14.9
13.4
11.4
3.4
0.7
0.7
0.4
0

income-statement-row.row.interest-income

220.810190.8102.6
1.9
2
2
1.2
0.7
1.2
2.7
2.2
2.4
1.4
1.1
0.1
0.2
0.2
0.3
0.2
0.3
0
0
0
0
0

income-statement-row.row.interest-expense

1.8601.32.8
1.5
0.7
1.1
1.6
1.7
1.9
3.4
3
0.8
0.4
1.2
0.5
0.7
0.5
0.3
0.2
0.4
0.3
0
0.1
0.1
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

855.070296.5-90.9
0.3
0.6
0.2
0
-0.4
-0.2
1.1
0.2
-2.3
-0.2
-1.1
1.1
0
-0.3
0
-0.2
0.4
-0.4
0
0
0
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

1.370301.8-89.9
0.5
0.9
0.3
0
0.1
-0.2
1.2
0.3
-0.1
0.3
0.1
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.total-operating-expenses

855.070296.5-90.9
0.3
0.6
0.2
0
-0.4
-0.2
1.1
0.2
-2.3
-0.2
-1.1
1.1
0
-0.3
0
-0.2
0.4
-0.4
0
0
0
0

income-statement-row.row.interest-expense

1.8601.32.8
1.5
0.7
1.1
1.6
1.7
1.9
3.4
3
0.8
0.4
1.2
0.5
0.7
0.5
0.3
0.2
0.4
0.3
0
0.1
0.1
0

income-statement-row.row.depreciation-and-amortization

2420156.686.8
4
4.8
5.1
4.9
5.3
6.5
8.1
6.4
4.5
4.8
4.2
2.2
1.8
1.4
1.3
1.1
0.9
0.7
0.1
0
0
0

income-statement-row.row.ebitda-caps

-451.37---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-695.260-466.117553.3
215.6
68.6
45.3
45.4
0.5
3.7
1.9
9.9
-21.2
3.4
-13.4
42.1
15.8
13.5
0.4
-5
-4.9
-0.9
-0.1
-0.4
-0.4
0

income-statement-row.row.income-before-tax

159.99025.217563
216.6
70.8
46.6
45
-0.4
2.8
2.3
9.4
-19.6
4.7
-13.3
41.6
15.2
13.2
0.4
-5
-5
-1.1
-0.2
-0.5
-0.4
0

income-statement-row.row.income-tax-expense

-70.830-62.93104.1
31.4
5.6
10.5
8.3
2.7
3
2.1
-2.2
-0.9
5.1
-0.7
11.1
3
2
0.1
0.2
-0.8
0.3
0
0.1
0
0

income-statement-row.row.net-income

239.610113.98467.5
110.4
44.9
21.8
25.8
-0.6
-1.4
-1.5
7.4
-14.9
-0.8
-8.5
20
8
7.7
-0.7
-5.1
-4.7
-0.9
-0.2
-0.5
-0.4
0

Frequently Asked Question

What is Sinovac Biotech Ltd. (SVA) total assets?

Sinovac Biotech Ltd. (SVA) total assets is 14114568000.000.

What is enterprise annual revenue?

The annual revenue is 420875000.000.

What is firm profit margin?

Firm profit margin is -0.470.

What is company free cash flow?

The free cash flow is -1.317.

What is enterprise net profit margin?

The net profit margin is -0.840.

What is firm total revenue?

The total revenue is -3.585.

What is Sinovac Biotech Ltd. (SVA) net profit (net income)?

The net profit (net income) is 0.000.

What is firm total debt?

The total debt is 74673000.000.

What is operating expences number?

The operating expences are 0.000.

What is company cash figure?

Enretprise cash is 1643026000.000.